Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study

BACKGROUND: Anti-angiogenic therapy is known to induce a greater degree of hypoxia, including in glioblastoma (GBM). Evofosfamide (Evo) is a hypoxia-activated prodrug which is reduced, leading to the release of the alkylating agent bromo-isophosphoramide mustard. We assessed the safety, tolerability...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Brenner, Andrew, Zuniga, Richard, Sun, Jessica D, Floyd, John, Hart, Charles P, Kroll, Stew, Fichtel, Lisa, Cavazos, David, Caflisch, Laura, Gruslova, Aleksandra, Huang, Shiliang, Liu, Yichu, Lodi, Alessia, Tiziani, Stefano
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6071657/
https://ncbi.nlm.nih.gov/pubmed/29415215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados